Theseus Pharmaceuticals, Inc. Banner Image

Theseus Pharmaceuticals, Inc.

  • Ticker THRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Theseus Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all classes of cancer-causing and resistance mutations that lead to clinicallyMore relevant variants in a particular protein in a given type of cancer. Theseus is developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and a next-generation, highly selective, pan-variant KIT inhibitor for the treatment of early-line GIST.
5.0 / 5.0 (1)

Theseus Pharmaceuticals, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.

Theseus Pharmaceuticals, Inc.

Most Recent Annual Report

Theseus Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Theseus Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!